FDA AdCommittee Backs 6 Indications for Celltrion’s Biosimilar of Remicade

An FDA advisory committee gave Celltrion’s biosimilar candidate for Remicade a strong show of support Feb. 9, backing its approval for six different indications.
Source: Generic Line